OX2 Therapeutics
Novel CheckPoint Inhibitor that is peptide base -- outperforms PD-1 and CTLA-4
- Stage Product In Development
- Industry Biotechnology
- Location Minneapolis, MN, USA
- Currency USD
- Founded July 2017
- Employees 4
- Incorporation Type C-corp
- Website ox2therapeutics.com
Team
-
CEO
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.